Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of CRC in Average-Risk Adults (Guardant Health)

PALO ALTO, Calif.–(BUSINESS WIRE)– Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the availability of Shield™, the company’s first blood-based test for the detection of early-stage colorectal cancer (CRC). The test, which only requires patients to complete a simple blood draw, is intended for adults age 45 and older who are not up to date with recommended screening guidelines, show no symptoms, and are at average risk for CRC.